HIGH-RISK PROSTATE CANCER
Clinical trials for HIGH-RISK PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new HIGH-RISK PROSTATE CANCER trials appear
Sign up with your email to follow new studies for HIGH-RISK PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can epigenetic drugs make prostate tumors more vulnerable to the immune system?
Disease control Recruiting nowThis early-stage study tests whether giving an epigenetic therapy before prostate removal surgery is safe and can help the immune system better attack the cancer. About 20 men with high-risk prostate cancer will receive the drug before their scheduled prostatectomy. The main goal…
Matched conditions: HIGH-RISK PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: Edwin Posadas, MD • Aim: Disease control
Last updated May 26, 2026 03:17 UTC
-
New radioactive treatment tested before prostate removal
Disease control Recruiting nowThis study tests a new radioactive drug (Tb-PSMA) given before surgery to remove the prostate in men with high-risk prostate cancer. The goal is to see if it is safe and helps improve cancer control. About 20 men will take part. The drug has shown promise in advanced cancer but i…
Matched conditions: HIGH-RISK PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Rabin Medical Center • Aim: Disease control
Last updated May 26, 2026 03:11 UTC
-
New drug cocktail aims to wipe out tough prostate tumors before surgery
Disease control Recruiting nowThis study tests whether taking a targeted drug (capivasertib) along with stronger hormone therapy before prostate surgery can shrink or destroy high-risk prostate cancers that have a specific genetic change (PTEN loss). About 30 men with localized but aggressive prostate cancer …
Matched conditions: HIGH-RISK PROSTATE CANCER
Phase: PHASE2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated May 26, 2026 03:09 UTC
-
Triple-Drug attack before surgery shows promise for High-Risk prostate cancer
Disease control Recruiting nowThis study tests whether giving a combination of hormone therapy, darolutamide, and pembrolizumab before prostate surgery, followed by pembrolizumab after surgery, can reduce or eliminate cancer in high-risk prostate cancer patients. About 40 men with aggressive, non-spread prost…
Matched conditions: HIGH-RISK PROSTATE CANCER
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New radiation approach aims to improve prostate cancer outcomes
Disease control Recruiting nowThis study tests a new type of radiation therapy for men with high-risk prostate cancer that has not spread. The new approach uses advanced imaging to deliver a higher dose of radiation directly to the main tumor while also treating the surrounding pelvic area. The goal is to see…
Matched conditions: HIGH-RISK PROSTATE CANCER
Phase: NA • Sponsor: Center Eugene Marquis • Aim: Disease control
Last updated May 18, 2026 12:12 UTC
-
New hope for High-Risk prostate cancer: which targeted radiation works best?
Disease control Recruiting nowThis early-stage study tests two types of targeted radiation therapy (177Lu-PSMA-617 and 225Ac-PSMA-617) in 45 men with high-risk prostate cancer who are scheduled for prostate removal surgery. The goal is to see which therapy delivers more radiation to the tumor and how it affec…
Matched conditions: HIGH-RISK PROSTATE CANCER
Phase: PHASE1 • Sponsor: Thomas Hope • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New scan cuts radiation and time for prostate cancer patients
Diagnosis Recruiting nowThis study tests a new way to do PET/CT scans for people with high-risk prostate cancer. Instead of two full scans, it uses one CT and a delayed PET scan 90 minutes after injection, which reduces radiation exposure and time in the hospital. Researchers will check if the images ar…
Matched conditions: HIGH-RISK PROSTATE CANCER
Phase: NA • Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Diagnosis
Last updated May 26, 2026 03:06 UTC
-
New study explores how genetic risk info shapes prostate cancer screening choices in BRCA carriers
Knowledge-focused Recruiting nowThis study looks at how men aged 45-70 with BRCA1/2 gene mutations respond to additional genetic risk testing for prostate cancer. Researchers want to understand how this information affects their decisions about prostate cancer screening and their emotional reactions. The study …
Matched conditions: HIGH-RISK PROSTATE CANCER
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 26, 2026 03:11 UTC
-
New scan method could revolutionize prostate cancer monitoring
Knowledge-focused Recruiting nowThis study looks at whether a special type of PET scan (PSMA PET) can better track how well prostate cancer treatment is working. It involves 110 men with newly diagnosed, aggressive prostate cancer. They will get a PSMA PET scan before treatment and another one after treatment t…
Matched conditions: HIGH-RISK PROSTATE CANCER
Sponsor: Xijing Hospital • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC